Acadian Asset Management LLC Eagle Pharmaceuticals, Inc. Transaction History

Acadian Asset Management LLC

$32.2 Billion
Q3 2024

A detailed history of Acadian Asset Management LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 7,155 shares of EGRX stock, worth $4,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,155

Previous 26,390 72.89%

Holding current value

$4,650

Previous $147,000 82.31%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.71 - $6.07 $71,361 - $116,756	-19,235 Reduced 72.89%	7,155 $26,000
Q2 2024 Aug 06, 2024	SELL	$3.34 - $5.6 $87,027 - $145,913	-26,056 Reduced 49.68%	26,390 $147,000
Q1 2024 May 10, 2024	SELL	$4.26 - $6.51 $1 Million - $1.53 Million	-235,109 Reduced 81.76%	52,446 $274,000
Q4 2023 Feb 13, 2024	BUY	$4.63 - $15.21 $234,523 - $770,432	50,653 Added 21.38%	287,555 $1.5 Million
Q3 2023 Nov 13, 2023	BUY	$15.21 - $22.88 $187,478 - $282,018	12,326 Added 5.49%	236,902 $3.73 Million
Q2 2023 Aug 07, 2023	BUY	$17.74 - $31.87 $162,232 - $291,451	9,145 Added 4.24%	224,576 $4.36 Million
Q1 2023 May 11, 2023	SELL	$25.06 - $34.09 $404,869 - $550,758	-16,156 Reduced 6.98%	215,431 $6.11 Million
Q4 2022 Feb 14, 2023	SELL	$24.98 - $39.77 $1.99 Million - $3.17 Million	-79,633 Reduced 25.59%	231,587 $6.77 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $3.29 Million - $5.86 Million	124,347 Added 66.54%	311,220 $8.22 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $3.29 Million - $5.86 Million	124,347 Added 66.54%	311,220 $8.22 Million
Q2 2022 Aug 09, 2022	BUY	$41.26 - $51.35 $1.95 Million - $2.42 Million	47,178 Added 33.77%	186,873 $8.3 Million
Q1 2022 May 12, 2022	BUY	$44.58 - $52.6 $1.51 Million - $1.78 Million	33,816 Added 31.94%	139,695 $6.91 Million
Q4 2021 Feb 10, 2022	SELL	$45.82 - $56.9 $1.08 Million - $1.34 Million	-23,551 Reduced 18.2%	105,879 $5.39 Million
Q3 2021 Nov 12, 2021	SELL	$43.79 - $55.78 $5.79 Million - $7.38 Million	-132,273 Reduced 50.54%	129,430 $7.21 Million
Q2 2021 Aug 11, 2021	BUY	$36.86 - $44.5 $1.79 Million - $2.17 Million	48,694 Added 22.86%	261,703 $11.2 Million
Q1 2021 May 11, 2021	BUY	$40.32 - $50.97 $1.67 Million - $2.12 Million	41,525 Added 24.22%	213,009 $8.89 Million
Q4 2020 Feb 11, 2021	BUY	$41.72 - $51.34 $116,190 - $142,981	2,785 Added 1.65%	171,484 $7.99 Million
Q3 2020 Nov 09, 2020	BUY	$37.02 - $51.28 $1.87 Million - $2.6 Million	50,643 Added 42.9%	168,699 $7.17 Million
Q2 2020 Aug 12, 2020	BUY	$43.24 - $55.02 $1.3 Million - $1.65 Million	30,043 Added 34.13%	118,056 $5.66 Million
Q1 2020 May 11, 2020	BUY	$34.37 - $60.07 $2.21 Million - $3.87 Million	64,413 Added 272.94%	88,013 $4.05 Million
Q4 2019 Feb 06, 2020	SELL	$54.32 - $64.31 $374,427 - $443,288	-6,893 Reduced 22.61%	23,600 $1.42 Million
Q3 2019 Nov 07, 2019	SELL	$53.25 - $59.98 $233,235 - $262,712	-4,380 Reduced 12.56%	30,493 $1.73 Million
Q2 2019 Aug 08, 2019	BUY	$46.61 - $58.45 $1.43 Million - $1.8 Million	30,725 Added 740.72%	34,873 $1.94 Million
Q1 2019 May 09, 2019	BUY	$38.66 - $51.82 $44,072 - $59,074	1,140 Added 37.9%	4,148 $210,000
Q4 2018 Feb 07, 2019	BUY	$36.72 - $67.73 $49,792 - $91,841	1,356 Added 82.08%	3,008 $121,000
Q3 2018 Oct 30, 2018	BUY	$66.65 - $83.86 $110,105 - $138,536	1,652 New	1,652 $115,000
Q1 2018 Apr 12, 2018	SELL	$52.16 - $66.86 $196,173 - $251,460	-3,761 Closed	0 $0
Q4 2017 Jan 18, 2018	SELL	$49.6 - $60.87 $192,249 - $235,932	-3,876 Reduced 50.75%	3,761 $201,000
Q3 2017 Oct 13, 2017	BUY	$46.62 - $60.36 $356,036 - $460,969	7,637	7,637 $456,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $8.46M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Eagle Pharmaceuticals, Inc. Transaction History